The Medical Imaging and Technology Alliance PET Group has rebranded as the Radiopharmaceutical Manufacturers and Theranostics Alliance. RMTA is a division of the National Electrical Manufacturers Association.
The new name reflects an expanded focus beyond diagnostic radiopharmaceuticals. The alliance said it will also focus on theranostics, including approaches used in cancer, heart disease, and Alzheimer’s disease.
RMTA said it will continue the MITA PET Group’s work on federal policies affecting diagnostic and therapeutic radiopharmaceuticals.
The group brings together developers of diagnostic and therapeutic radiopharmaceuticals with manufacturers of isotopes, contrast agents, nuclear imaging technologies, and integrated theranostic platforms.
The alliance said it will work with policymakers and stakeholders to address access barriers, modernize regulatory and reimbursement frameworks, and advance policies related to safety and quality across radiopharmaceuticals and theranostics.
RMTA describes itself as the collective voice for the radiopharmaceutical and contrast-agent sector. The group is based in Arlington, VA.
Company:RMTA
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
